Search results for "DISEASE PROGRESSION"

showing 10 items of 835 documents

Six-minute walk test in moderate to severe heart failure with preserved ejection fraction: Useful for functional capacity assessment?

2015

Despite improvements in medical treatment and prevention, heart failure (HF) remains a major cause of morbidity and mortality worldwide [1]. Currently, HF with preserved ejection fraction (HFpEF) has become the most prevalent form of HF in elderly patients [2,3]. The cardinal features in HF, aside from left ventricular systolic function, are exertional dyspnea and reduced aerobic capacity. Although the most accurate expression of exercise tolerance and severity in HF is measured by peak oxygen uptake (peak VO2), its assessment is not widely available in daily clinical practice.  This work was supported in part by grants from: Sociedad Española de Cardiología: Investigación Clínica en Cardio…

MaleModerate to severeGerontologySIX MINUTE WALKmedicine.medical_specialtyCapacity assessmentSix-minute walk testWalking030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicinePeak VO2AgedHeart Failurebusiness.industryDisease progressionStroke VolumeStroke volumemedicine.diseaseHeart failure with preserved ejection fractionHeart failureDisease ProgressionExercise TestCardiologyFunctional capacity assessmentFemaleCardiology and Cardiovascular MedicinePeak vo2Heart failure with preserved ejection fractionbusinessInternational Journal of Cardiology
researchProduct

Management of elderly patients suffering from cancer: Assessment of perceived burden and of quality of life of primary caregivers

2017

International audience; Objective: To evaluate the perceived burden and the quality of life (QoL) at 3 and 6 months of the primary caregiver (PC) of patients aged 70 and over suffering from cancer and the predictors of QoL in this population.Methods: In this prospective observational study, 98 patients aged 70 and older with cancer and 96 PCs were included between 01/06/2014 and 18/03/2015. The Medical Outcomes Study 12-item Short Form Health Survey (SF-12) was used to assess the QoL of PCs and the Zarit Burden Interview (ZBI) was used to measure the perceived burden at 3 and 6 months. The major determinants of QoL were identified using mixed linear models for the dimensions of the SF-12 th…

MaleMultivariate analysisActivities of daily livingTime Factors0302 clinical medicineQuality of lifeCost of IllnessNeoplasmsSurveys and QuestionnairesActivities of Daily Living030212 general & internal medicineLongitudinal StudiesProspective StudiesProspective cohort studyPrimary caregiverAged 80 and overeducation.field_of_studyFamily caregivers[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyillnessAge FactorsMiddle Agedcomprehensive geriatric assessmentolder patientshumanities3. Good healthcomorbidityOncologyCaregivers030220 oncology & carcinogenesisdepressionDisease ProgressionimpactFemalefamily caregiversoncology consultationQuality of lifemedicine.medical_specialtyGeriatric oncology consultationPopulationBurden[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology03 medical and health sciencesmedicineHumanscareeducationbreast-cancerbusiness.industrymedicine.diseaseComorbidityPhysical therapyObservational studyGeriatrics and Gerontologybusiness
researchProduct

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, second…

2002

Abstract Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit+ secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response…

MaleMyeloidmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsBiochemistryTyrosine-kinase inhibitorPiperazinesBone MarrowRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary Acute Myeloid LeukemiaHumansReceptors Platelet-Derived Growth FactorEnzyme InhibitorsneoplasmsSalvage TherapyChemotherapyAnemia Refractory with Excess of Blastsbusiness.industryAnemia RefractoryDaunorubicinRemission InductionCytarabineMyeloid leukemiaCell BiologyHematologyExonsMiddle Agedmedicine.diseaseNeoplasm ProteinsLeukemiaLeukemia Myeloid AcuteProto-Oncogene Proteins c-kitmedicine.anatomical_structureImatinib mesylatePyrimidinesDrug Resistance NeoplasmImmunologyBenzamidesCancer researchDisease ProgressionImatinib MesylateNeoplastic Stem CellsBone marrowbusinessBlood
researchProduct

Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

2022

Objective: This study was undertaken to describe and compare disease course and prognosis of early (ie, disease onset before age 11 years) and late (ie, disease onset after age 11 years) onset pediatric multiple sclerosis. Methods: Prospectively collected clinical information from Italian Multiple Sclerosis Register of 1993 pediatric multiple sclerosis patients, of whom 172 had early onset, was analyzed. Cox models adjusted for sex, baseline Expanded Disability Status Scale score, and disease-modifying treatments and stratified for diagnostic criteria adopted (Poser vs McDonald) were used to assess the risk of reaching irreversible Expanded Disability Status Scale scores of 3, 4, and 6, and…

MaleNatural History of Multiple SclerosisMultiple SclerosisNeurologyRecurrencePediatric Multiple SclerosisDisease ProgressionHumansDisabled PersonsSettore MED/26 - NeurologiaNeurology (clinical)ChildPrognosis
researchProduct

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney dis…

2021

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. Methods: We evaluated 2445 CKD patients (2010–2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laborator…

MaleNephrologymedicine.medical_specialtyAutosomal dominant polycystic kidney diseaseRenal functionComorbiditylcsh:RC870-923urologic and male genital diseasesCarotid Intima-Media ThicknessAsymptomaticNephropathyAutosomal dominant polycystic kidney diseaseInternal medicineChronic kidney diseasemedicineHumansAnkle Brachial Indexcardiovascular diseasesRenal Insufficiency ChronicProteinuriabusiness.industryMiddle AgedPolycystic Kidney Autosomal DominantPrognosislcsh:Diseases of the genitourinary system. Urologymedicine.diseaseCardiovascular diseasePlaque Atheroscleroticfemale genital diseases and pregnancy complicationsNephropathyCor MalaltiesBlood pressureCardiovascular DiseasesHeart Disease Risk FactorsNephrologyDisease ProgressionInsuficiència renal crònicaFemalemedicine.symptombusinessResearch ArticleKidney disease
researchProduct

Early and mid-term effects of obstructive apneas in myocardial injury and inflammation.

2011

Abstract Background Obstructive sleep apnea (OSA) is associated with cardiovascular disorders, but the different comorbidities in OSA patients make it difficult to know their specific effects on the development of cardiovascular injury. The aim of the present study was to investigate whether recurrent obstructive apneas could lead to myocardial injury. Methods Thirty-six male Sprague–Dawley rats (300–350 g) were either acutely (3 h) or sustainably (5 h/day, for 10 days) subjected to obstructive apneas with a pattern of 15 s each, 60 apneas/h. Corresponding control groups were formed for the acute and sustained models. To assess the induction of systemic inflammation, IL1-β was measured in p…

MaleObstructive sleep apnea Myocardial injury Inflammation Animal modelsmedicine.medical_specialtyPathologyHeart diseaseHeart DiseasesInterleukin-1betaInflammationApoptosisSettore MED/10 - Malattie Dell'Apparato RespiratorioSystemic inflammationRats Sprague-DawleyInternal medicinemedicineAnimalsInflammationSleep Apnea Obstructivebusiness.industryMyocardiumSleep apneaGeneral Medicinemedicine.diseaseRatsObstructive sleep apneaDisease Models AnimalApoptosisInitial phaseAcute DiseaseCardiologyDisease ProgressionCardiovascular Injurymedicine.symptombusinessSleep medicine
researchProduct

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to pre…

2014

Background Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. Methods mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients a…

MaleOncologyCHOPEquilibrative nucleoside transporter 1BioinformaticsDeoxycytidineCohort StudiesPancreatic ductal adenocarcinomachemistry.chemical_compoundMedicine(all)Transcription Factor CHOPbiologyDCKGeneral MedicineMiddle AgedSurvival RateDisease ProgressionAdenocarcinomaFemaleMRP1DeoxycytidineMultidrug Resistance-Associated ProteinsCarcinoma Pancreatic Ductalmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaMalignancyhENT1General Biochemistry Genetics and Molecular BiologyEquilibrative Nucleoside Transporter 1Internal medicinemedicineHumansRNA MessengerSurvival rateAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchRECPAMmedicine.diseaseGemcitabineGemcitabinechemistrybiology.proteinPancreatic ductal adenocarcinoma hENT1 CHOP MRP1 DCK RECPAMbusinessTranscription Factor CHOPCHOP
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker…

2017

Abstract Background Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patients and methods Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and day 8/q3w with (arm A) or without panitumumab (arm B; 9 mg/kg BW, i.v q3w). The primary end-point was the evaluation of progression-free survival (PFS) at 6 months. Secondary end-points included objective response rate (ORR), ov…

MaleOncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier Estimatemedicine.disease_causeDeoxycytidine0302 clinical medicineRisk FactorsGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicinePrecision MedicineAged 80 and overPanitumumabAntibodies MonoclonalCombination chemotherapyMiddle AgedIsocitrate DehydrogenaseBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)Female030211 gastroenterology & hepatologyKRASmedicine.drugAdultmedicine.medical_specialtyAdolescentDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Young Adult03 medical and health sciencesInternal medicineBiomarkers TumorHumansPanitumumabAgedCisplatinChemotherapybusiness.industryGene Expression ProfilingGemcitabineGemcitabineClinical trialMutationCisplatinbusinessEuropean Journal of Cancer
researchProduct

Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers

2011

Abstract Mast cells (MC) are c-Kit–expressing cells, best known for their primary involvement in allergic reactions, but recently reappraised as important players in either cancer promotion or inhibition. Here, we assessed the role of MCs in prostate tumor development. In prostate tumors from both tumor-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and human patients, MCs are specifically enriched and degranulated in areas of well-differentiated (WD) adenocarcinoma but not around poorly differentiated (PD) foci that coexist in the same tumors. We derived novel TRAMP tumor cell lines, representative of WD and PD variants, and through pharmacologic stabilization or geneti…

MaleOncologyCancer Researchmedicine.medical_specialtyEpithelial-Mesenchymal TransitionMice TransgenicAdenocarcinomaBiologymedicine.disease_causeCell DegranulationMiceProstate cancerProstateCell Line TumorInternal medicineTumor MicroenvironmentmedicineMast CellAnimalsHumansMast CellsReceptors Tumor Necrosis Factor Member 25Tumor microenvironmentAdenocarcinoma; Animals; Carcinoma Neuroendocrine; Cell Degranulation; Cell Line Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Humans; Male; Mast Cells; Matrix Metalloproteinase 9; Mice; Mice Inbred C57BL; Mice Transgenic; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Receptors Tumor Necrosis Factor Member 25; Tumor Microenvironment; Cancer Research; OncologyAnimalProstatic NeoplasmsCancermedicine.diseasehumanitiesCarcinoma NeuroendocrineMice Inbred C57BLProto-Oncogene Proteins c-kitmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyTumor progressionProstatic NeoplasmDisease ProgressionAdenocarcinomaCarcinogenesisHumanTramp
researchProduct